The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.00
Bid: 295.00
Ask: 299.00
Change: 0.00 (0.00%)
Spread: 4.00 (1.356%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 296.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS REPORTS: Elementis swings to profit; Hutchmed changes CEO

Thu, 03rd Mar 2022 13:02

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Elementis PLC - London-based speciality chemicals - Swings to profit in 2021, with pretax profit of USD5.8 million, up from a loss of USD68.8 million in 2020. Strong new business momentum, targeted pricing actions and volume recovery boost revenue by 17% in the year to USD880 million from USD751 million the year before. Dividends may be reinstated in the medium term, but remain suspended. For 2022, global supply chain issues and cost inflation are a concern, but it is off to "an encouraging start".

----------

Synthomer PLC - Essex-based chemicals company - Profit before tax rockets in 2021 to GBP283.9 million from GBP20.3 million in 2020, as revenue is up 42% to GBP2.33 billion from GBP1.64 billion. Underlying pretax profit more than doubles to GBP420.1 million from GBP160.0 million. Profit is being used to make "major inorganic and organic investments" to support further growth. In 2022 so far, nitrile latex demand is "subdued" as Covid eases and inventories of medical gloves are high, while all other divisions have started 2022 well. Final dividend is 21.3 pence, over double that of 8.3p in 2020, for a total in 2021 of 30.0p, up from 11.6p the prior year.

----------

Glanbia PLC - Kilkenny, Ireland-based nutrition company - Revenue comes in ahead of expectations for 2021 at EUR4.20 billion, up 9.8% from EUR3.82 billion in 2020. Profit before tax rises 21% to EUR158.0 million from EUR131.1 million. Says performance was driven by strong global consumer demand. A final dividend of 17.53 cents is proposed, bringing the year's total to 29.28 cents, up 10% on 2020, and launches new EUR50 million share buyback. Growth in revenue is expected for 2022, and says inflationary costs will be managed with higher sales prices.

----------

Galliford Try Holdings PLC - Uxbridge, England-based construction company - Pretax profit up to GBP7.1 million in first half ended December 31 from GBP4.1 million a year before. Revenue is up 10% to GBP594 million from GBP542 million in the prior year. Order book is up to GBP3.4 billion from GBP3.3 billion a year ago. The company boosts interim dividend by 83% to 2.2 pence from 1.2p the year before. Outlook for the rest of the year is positive, with 95% of projected revenue already secured.

----------

Empiric Student Property PLC - London-based owner and operator of student accommodation - Swings to profit in 2021, with a pretax profit of GBP29.2 million from a pretax loss of GBP24.0 million. Net rental inome drops 11% year-on-year to GBP32.9 million from GBP32.9 million, with total revenue down 6% to GBP56.0 million from GBP59.4 million. Dividends resume in fourth quarter, with payment of 2.5p, and targets fully covered and progressive dividends going forward, to increase as occupancy rates normalise. For the academic year starting in 2022, Empiric expects to come in at the top of its 85% to 95% target occupancy rate.

----------

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical company - Total revenue for 2021 is USD356.1 million up 56% year-on-year from USD228.0 million. Loss before tax of USD215.7 million widens from USD189.7 million in FY20. Momentum is continuing into 2022, and it held over USD1 billion in cash on December 31. Christian Hogg retires as chief executive officer, after 22 years with the company and 15 years as CEO. Promotes Chief Scientific Officer Weiguo Su, a 17-year company veteran, to CEO. The changes are effective from Friday.

----------

AIB Group PLC - Dublin-based bank - Swings to pretax profit of EUR629 million in 2021 from a loss of EUR931 million. Net interest income drops 4% to EUR1.79 billion from EUR1.87 billion the prior year. Gross loans were down 2% to EUR56.5 billion from EUR59.4 billion. Recommends dividend of 4.5 pence per share for the year, with no dividend having been paid in 2021. AIB expects net interest income to be "stable" in 2022.

----------

Hunting PLC - London-based energy services - In 2021, revenue drops 17% to USD521.6 million from USD626.0 million in 2020, but pretax loss from operations narrows to USD85.5 million from USD223.0 million. Second half of 2021 lifted by improved trading and recovering commodity prices, after first half hit by global reduction in activity in oil & gas. A final dividend of 4.0 cents will be paid out for the year, unchanged from 2020. As Covid-related operational issues ease in its first quarter, it predicts a "much improved" 2022.

----------

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
12 Sep 2023 11:26

Hutchmed reports progress on two oncology fronts

(Sharecast News) - Hutchmed China reported significant strides in oncology research on Tuesday, completing patient enrollment for a bridging study of tazemetostat, and announcing pivotal results for the phase 3b clinical trial of savolitinib.

Read more
12 Sep 2023 10:26

IN BRIEF: Hutchmed China finalises patient enrolment for Tazemetostat

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Completes patient enrolment for bridging phase two study in China to evaluate the efficacy of cancer drug Tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma. Tazemetostat is approved by the US Food & Drug Administration for the treatment of advanced epithelioid sarcoma and R/R FL.

Read more
29 Aug 2023 13:38

Hutchmed tumour therapy candidate gets breakthrough designation

(Sharecast News) - Pharmaceuticals developer Hutchmed China announced on Tuesday that the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) has granted breakthrough therapy designation (BTD) to its investigational drug savolitinib.

Read more
29 Aug 2023 09:30

IN BRIEF: China grants Hutchmed's savolitinib breakthrough therapy tag

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Wins 'breakthrough therapy designation' in China for its gastric cancer treatment, savolitinib. The BTD is granted by the National Medical Products Administration. It is for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with mesenchymal epithelial transition factor amplification who have failed at least two lines of standard therapies. Hutchmed notes that MET-driven gastric cancer has a poor prognosis, and China grants a BTD to new drugs that treat life-threatening diseases for which there are no effective treatment options.

Read more
21 Aug 2023 08:46

Hutchmed China hails trial on sovleplenib meeting primary endpoint

(Alliance News) - Hutchmed (China) Ltd on Monday said a phase 3 trial evaluating the investigational use of sovleplenib met its primary endpoint.

Read more
21 Aug 2023 08:24

Hutchmed meets all endpoints in platelet disorder treatment trial

(Sharecast News) - Hutchmed China reported a breakthrough from its recent phase three trial in sovleplenib on Monday, reporting that it met its primary endpoint and all secondary endpoints for treating adult patients with primary immune thrombocytopenia - a platelet disorder - (ITP) in China.

Read more
31 Jul 2023 12:47

Hutchmed swings to profit after "sharpening goals and priorities"

(Alliance News) - Hutchmed (China) Ltd on Monday reported sharp first-half revenue growth, as a strategy change to boost its fortunes outside of China saw early fruit.

Read more
24 Jul 2023 15:46

UK earnings, trading statements calendar - next 7 days

Tuesday 25 July 
City of London Investment Group PLCTrading Statement
Compass Group PLCTrading Statement
Croda International PLCHalf Year Results
Games Workshop Group PLCFull Year Results
Greencore Group PLCTrading Statement
Hummingbird Resources PLCTrading Statement
MITIE Group PLCTrading Statement
Paragon Banking Group PLCTrading Statement
Reach PLCHalf Year Results
Smart Metering Systems PLCTrading Statement
Tristel PLCTrading Statement
Tyman PLCHalf Year Results
Unilever PLCHalf Year Results
Unite Group PLCHalf Year Results
Wednesday 26 July 
Aptitude Software Group PLCHalf Year Results
Breedon Group PLCHalf Year Results
Conduit Holdings LtdHalf Year Results
Ecora Resources PLCTrading Statement
Fresnillo PLCTrading Statement
FRP Advisory Group PLCFull Year Results
Gresham Technologies PLCHalf Year Results
Lloyds Banking Group PLCHalf Year Results
Marston's PLCTrading Statement
Nichols PLCHalf Year Results
Primary Health Properties PLCHalf Year Results
Rathbones Group PLCHalf Year Results
Revolution Bars Group PLCTrading Statement
Rio Tinto PLCHalf Year Results
Science Group PLCHalf Year Results
Van Elle Holdings PLCFull Year Results
Thursday 27 July 
Allianz Technology Trust PLCHalf Year Results
Antofagasta PLCHalf Year Results
Capital & Regional PLCHalf Year Results
Card Factory PLCTrading Statement
Checkit PLCTrading Statement
Drax Group PLCHalf Year Results
Deliveroo PLCHalf Year Results
Derwent London PLCHalf Year Results
Entain PLCHalf Year Results
Greencoat UK Wind PLCHalf Year Results
Global Connectivity PLCHalf Year Results
Hostelworld Group PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Lancashire Holdings LtdHalf Year Results
Mitchells & Butlers PLCTrading Statement
OSB Group PLCHalf Year Results
Persimmon PLCHalf Year Results
Petrofac LtdHalf Year Results
Redcentric PLCFull Year Results
S&U PLCTrading Statement
Savills PLCHalf Year Results
Secure Trust Bank PLCHalf Year Results
Spirax-Sarco Engineering PLCHalf Year Results
Videndum PLCHalf Year Results
Wheaton Precious Metals CorpHalf Year Results
Friday 28 July 
AIB Group PLCHalf Year Results
GCP Infrastructure Investments LtdTrading Statement
International Consolidated Airlines Group SAHalf Year Results
Intertek Group PLCHalf Year Results
Jardine Matheson Holdings LtdHalf Year Results
NatWest Group PLCHalf Year Results
PayPoint PLCFull Year Results
PayPoint PLCTrading Statement
Standard Chartered PLCHalf Year Results
YouGov PLCTrading Statement
Monday 31 July 
Hutchmed (China) LtdHalf Year Results
Pearson PLCHalf Year Results
Pod Point Group Holdings PLCHalf Year Results
Quartix Technologies PLCHalf Year Results
Spectris PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
20 Jul 2023 14:14

IN BRIEF: Hutchmed progresses fruquintinib designation and testing

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Granted breakthrough therapy designation, by the Center for Drug Evaluation of China's National Medical Products Administration, for oral inhibitor fruquintinib combined with PD-1 antibody sintilimab. BTD is for treatment of patients with previously treated advanced endometrial cancer.

Read more
10 Jul 2023 12:58

Hutchmed launches new phase one study in China

(Sharecast News) - Biopharmaceutical company Hutchmed China announced the launch of a phase one study in China for HMPL-415 on Monday - an investigational selective allosteric inhibitor that targeted Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2).

Read more
10 Jul 2023 08:53

IN BRIEF: Hutchmed starts study for tumour treatment in China

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases' treatment developer - Starts phase one study in China of its SHP2 inhibitor HMPL-415 for the treatment of advanced malignant solid tumours. First patient received their first dose on Thursday last week. Hutchmed expects up to 80 patients to take part in the study. SHP2 is a non-receptor protein tyrosine phosphatase which controls cell growth and cell migration.

Read more
16 Jun 2023 08:51

Hutchmed, Takeda Fresco-2 study published in The Lancet

(Alliance News) - Hutchmed (China) Ltd on Friday said phase three results for its Fresco-2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer, conducted alongside Takeda Pharmaceutical Co Ltd, were published in peer-reviewed journal, The Lancet.

Read more
16 Jun 2023 08:44

Hutchmed China's colorectal cancer study to be published

(Sharecast News) - Hutchmed China, alongside its partner Takeda, announced the publication of the phase three 'FRESCO-2' study results evaluating the use of fruquintinib in patients with previously-treated metastatic colorectal cancer (CRC) on Friday, in the Lancet medical journal.

Read more
15 Jun 2023 16:51

IN BRIEF: Hutchmed and Takeda get Europe marketing backing for drug

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases treatment developer - Says marketing authorisation application for fruquintinib, made alongside Tokyo-based Takeda Pharmaceutical Co Ltd, has been validated and caccepted by the European Medicines Agency. Fruquintinib is an inhibitor of vascular endothelial growth factor receptors used to treat cancers.

Read more
26 May 2023 13:13

US FDA gives priority to Hutchmed's colorectal cancer treatment

(Sharecast News) - Hutchmed China, in collaboration with Takeda, announced on Friday that the US Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) of fruquintinib.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.